Actively Recruiting
Molecular Classification in Mexican Patients With Endometrial Cancer and Its Impact on Prognosis
Led by National Institute of Cancerología · Updated on 2024-02-28
64
Participants Needed
1
Research Sites
152 weeks
Total Duration
On this page
Sponsors
N
National Institute of Cancerología
Lead Sponsor
G
GlaxoSmithKline
Collaborating Sponsor
AI-Summary
What this Trial Is About
Endometrial cancer (EC) is one of the most common gynecological neoplasms, being the second in incidence and third in mortality in Mexico. Recent studies show that EC molecular classification (Cancer Genome Atlas Research Network, 2013) serves to establish a more accurate prognosis in these patients and regulate therapeutic behavior in a personalized manner. However, there are no studies on EC molecular classification in Mexican women or its impact on prognosis and the possible modification of targeted treatment. The investigators will determine the molecular classification in EC by next-generation sequencing (NGS) to detect TP53 and POLE somatic mutations, and immunohistochemical detection of microsatellite instability (MSH2, MLH1, PMS1, PMS2, MSH6, and MSH3) in a cohort of patients with endometrioid-type EC, endometrioid subtype, attended at the Instituto Nacional de Cancerología - Mexico (INCan) and determine its impact on clinical prognosis.
CONDITIONS
Official Title
Molecular Classification in Mexican Patients With Endometrial Cancer and Its Impact on Prognosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinical diagnosis of endometrioid-type endometrial cancer with samples available
- Patients who have undergone surgery at Instituto Nacional de Cancerología (INCan)
You will not qualify if you...
- Samples with endometrial cancer of non-endometrioid type
- Samples from patients with double primary neoplasms, including ductal carcinoma in situ, squamous cell skin cancers, and cervical carcinoma in situ
- History of malignancy less than 5 years prior without evidence of disease (remission)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Instituto Nacional de Cancerología
Mexico City, Mexico City, Mexico, 14080
Actively Recruiting
Research Team
D
David F Cantu-de-León, PhD
CONTACT
D
Diddier Prada, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here